10月31日,武田制药发布了2024年上半年财报,透露出一个数字:BD引进和黄医药的呋喹替尼,在半年里获得231亿日元收入,约合1.51亿美元。这相当于2023年全年呋喹替尼在中国市场的销售额。呋喹替尼2018年就在国内获批了,用于结直肠癌的三线治疗,但中国市场销售一般。2023年1月,和黄医药将中国之外的全球权益授予武田,交易总额最高可达11.3亿美元,一度刷新了中国小分子新药出海授权的交易纪录...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.